Q3 Results Confirm Franchise Weakness; Guidance Cut Again
Read source articleWhat happened
Boston Scientific reported third-quarter revenues of $5.14 billion, up just 1.5% year over year, and adjusted EPS of $0.73, down 2.7%, as WATCHMAN and Electrophysiology continued to face procedure deceleration and competitive pressure. Management lowered expectations for the remainder of the year, marking another reset after prior cuts in April and July. The two franchises that previously justified a premium valuation now account for a shrinking contribution to growth, with total company expansion nearly stalling. This outcome aligns with the bear case scenario in the master report, which anticipated WATCHMAN growth near 0-5% and EP below 10%. The market is now questioning whether the stock has fully priced in the deterioration or if further downside remains.
Implication
The Q3 results materially weaken the base case, shifting the probability distribution toward the bear scenario with implied value near $38. Total revenue growth of 1.5% versus 7.5% in Q2 shows that the rest of the portfolio is no longer offsetting franchise-level weakness. Management's repeated guidance cuts have destroyed credibility, and the market will likely demand hard evidence of stabilization before re-rating the stock. Until WATCHMAN returns to double-digit growth and competitive language in EP disappears from filings, the stock lacks a positive catalyst. Investors should wait for the next two quarterly reports to confirm operational repair or consider exiting the recovery thesis.
Thesis delta
The master report's WAIT rating was based on a balanced risk-reward with a 3-6 month re-assessment window. Q3 results push the balance decisively toward the bear case, as WATCHMAN and EP show no stabilisation and total growth has collapsed. This reduces confidence in the base case and increases the likelihood of the stock testing the $38 bear-case implied value.
Confidence
High